Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you send this proposal to AMRNIR yet? If so any feedback?
Good Evening Bio! As I have been appointed as a chairperson for an AdHocCommittee in the case of the bankruptcy of a major insurer during the subprime crisis I am on first name basis with a number of NYC securities law advocates and counsellors. Some are still sending me seasons greetings...
If you feel you have a case documented I am happy to reach out to them.
Thx again. Took me all this time to read up on 200 post or so and now can see it has been submitted already when I posted my question to you... sorry for the redundancy...
Thx! Cant keep up with hundreds of posts every day and have not found out how to search for keyphrases... As soon as VASCEPA is approved in Europe I hope it will help my memory faculties but up to then I will probably only have sketchy recollections of the massive overload of input here...
BTW
how did the legal team get notified on this? Are you aware of any acknowledgement of the receipt of these slides?
Dear Jesse, thank you for your kind response! I fully understand where you are coming from. I used to teach and conduct continuing education programs on 3 continents and was well sought after for conferences until I fell really ill due to a massive lead poisoning in 2006 and had to cancel numerous appearences due to serious damage in the peripheral nervous system as well as my opticus not to mention liver, kidney etc.. .
Up to that point I also published at least quarterly. Within a single year invitations to conferences started to dwindle and after 3 years without new publications I was virtually forgotten even so far I had mostly repeat attendees at my seminars...
Anyway I digress:
the arrogance bred into the corporate mental DNA is staggering and I can just see it how they tried to ignore an outsider advising them on something they overlooked even so they got paid for finding it themselves... total NO GO area...
However trial lawyers are a different breed. They don't have to defend their corporate standing, home turf and territory. Usually they are highly incentivized for a positive trial outcome. Which is why they have huge research staffs that might be eager to get tipped off to an inroad they overlooked!
Maybe they would be attentive as well to the red flag of the slides of REDDY's presentation at JPM which was reported here to show an estimated income off Generic Vascepa of close to 800 m$!
Income that could never be made from a niche indication with a 2 week limitation as the sales of VASCEPA up to 2018 demonstrates.
I can tell you are frustrated and tired of another "IGNORE yet at this point we can need any bit of help and your insights are the most profound in my overview of all the various opinions voiced here over time.
Still you might consider reaching out to the research staff of the legal teams representing AMARIN.
IT might just do the trick!
Here is some good reporting on yesterdays day in the court:
https://www.twitlonger.com/show/n_1sr4bap
Looks positive to me!
On another note did you ever try to relay JL's arguments to the defence or Amarin IR?
If so did you receive a response?
Thank you for all your efforts on behalf of patients.
May you find the time to relax occasionally
what sort of fake link is this?
Dear Jesse, yor arguments are sublimely convincing and your expertise in the MoA of DHA and EPA unmatched.ThereforeI wold like to implore you to present your expertise and thoughts to the adressees you mentioned directly in your own name and with your full credentials as you laid them out out in your FDA AdHoc testimonial!
If I may I would like to make one more suggestion:
IF(!?!) Reddy or Hikma in fact presented an estimated income of 700+ million$ p.a. through their "generic Vascepa" product at JPM practically parallel to the first day in court it is obvious that such a projected turnover can never ever be achieved by a limited niche indication for pancreatitis and for a timeframe up to 12 weeks of prescriptions.
I hope you could include that slide of Reddy's presentation.
As much as I appreciate BioB's exuberance and excitability I fear the persuasivness of yur arguments might get tainted if the receipients might have felt pressured by BioB's proactive endeavours of the past.
I would certainly present your ideas myself but would not be able to answer any further questions if the arguments would raise interest to explore the issue.
Moreover in the US I am only able to present as a Dr.honoris causa so far less weighty than your CV.
Please give it some thought. I feel you may hold the keys for an immediate ruling in our favour
With warm regards,
Ratna
Cannot vouch for my memory being 100% correct but I do seem to recall that STREGTH also used corn oil as placebo. Maybe you are not in the dark but on to something!
Would it be possible for AMARIN to file for a court injunction to stop this practice due to reckless physical harm for patients?
Now that ACASTI has failed we are really the only one fighter left standing
Thank you for the encouragement!
I would like to think so too, yet MMs have the Bid/Ask already contained at a pathetic spread of 19.30 : 20.00$.....
not much - so far:
AMRN
18.95-1.04 (-5.20%)
At close: January 10 4:00PM EST
20.00 +1.05 (5.54%)
Pre-Market: 4:19AM EST
It is a sad yet simple truth that you can be invested in the right instrument but due to bad timing loose anyway. If you are not overleveraged and have some reserves to hold out through a trough and maybe average down (dont try martingaling so) you might very well come out even or better.
I accumulated a rather substantial position in AMRN up to ADCOM 1 and suffered the trauma of watching the FDA take us apart. To this day I can hear the confused mumbling of one of the docs on the panel who failed to understand the turnaround of the FDA guy as little as I did....
Due to Jesse and others on this board however I persisted and not even a decade later I am about to get rewarded even so I was so euphoric to add on ADCOM 2. again at recent highs..... so never rely on my take on timing yet even so I fail on tactics I made out on strategy after all..
Here is a most encouraging bit of news that popped up on my IB screen just now:
https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html
- even so it is not the monday morning news break some have hoped for it is a nice start of the day !
not get
Thx Tosca! Already read that article and as far as a timeline is concerned it is rather vague.
Gabor's list of events above in the stickies is really quite thorough but it does not adress the dozen or so references to other dates discussed in the various posts - possibly because they emerged after Gabor posted this in December?
In particular there seem to be a number of decisive turning points in the upcoming week starting on Mon. Jan.6th with a decision wether to allow Reduce-It results as evidence into the case which does seem to be vital from a layman's perspective. Additionally there seem to be some more decisions or injunctions coming up shortly which is what I try to find out .
Happy New Year One & All!
Hopefully this is the year that sees the end of all the roadblocks for fulfilment of all the positive prospects we have seen in Amarin's VASCEPA!
Just spent most of my Saturday reading up on the many hundreds of new posts. As long as we were waiting for AdCom and label expansion + Canada etc. it seemed like an annoying but after all trivial thing but now I am shocked about the prevalence this has taken and the serious undertone struck here...
Given the importance of this outcome I am surprised that I could not find a single post with a complete timeline of the legal dates and events unfolding in the patent case. I am sure somebody must have posted it but it is already going on sunset over here, so if it could be reposted again I would very much appreciate it!
If I may add - maybe a sticky would help to find it tomorrow. I am probably not the only one that can read up on all posts continuously.
Cheers!
Happy New Year One & All!
Hopefully this is the year that sees the end of all the roadblocks for fulfilment of all the positive prospects we have seen in Amarin's VASCEPA!
Just spent most of my Saturday reading up on the many hundreds of new posts. As long as we were waiting for AdCom and label expansion + Canada etc. it seemed like an annoying but after all trivial thing but now I am shocked about the prevalence this has taken and the serious undertone struck here...
Given the importance of this outcome I am surprised that I could not find a single post with a complete timeline of the legal dates and events unfolding in the patent case. I am sure somebody must have posted it but it is already going on sunset over here, so if it could be reposted again I would very much appreciate it!
If I may add - maybe a sticky would help to find it tomorrow. I am probably not the only one that can read up on all posts continuously.
Cheers!
Thx! I would like that! However so far I did rely on CBOE's regulations so far and that did not come up..
Also not NASDAQs fact sheet for options. The article is from 2010. Hopefully that is still an applicable rule !?
p.s.: if (?!) your theory holds true this would mean that an additional 1million plus shares at 21$ strike would be assigned adding up to over 63 k contracts in the money... so some 7.++ million shares need to be accumulated and delivered by tomorrow by option writers!
Thx, yet CBOE does not specify this practice:
http://www.cboe.com/education/getting-started/quick-facts/expiration-exercise-assignment
So I would still hope you can provide a source for your opinion
Could you kindly provide some quote or source for that assessment. It has escaped me so far that options are exercised according to AH trading levels....
My experience has bee that options get assigned according to closing price - which is why it is so heavily fought over
Thx, Berry! Very vivid imagery indeed! I Barely deal with diabetics except for comorbidity as my background is in psycho oncology. Just noticed that Keto seems to support most therapeutic approaches for cancer patients but doesn't seem to do much to counter weight loss even so it is loaded with fats and proteins...
Did you notice any difference in mental resilience with patients that are on VASCEPA?
Thank you for your informative response. I was not aware of the 1:1 translation of Diabetes to ED.
Makes VASCEPA even more potent!
p.s.. always enjoy your post from a nutritionist background.Vastly under appreciatedl
Do you have experience with KETO on Diabetes Type 2?
Dear Jesse, once more my heartfelt thanks for your clear elucidation of facts for oh so many years!
Watching in amazement how raging bulls on this otherwise supreme board of assorted experts turned into meek sheep clamoring to offer themselves up to the stockyards to be butchered for a buy out in the 30$ range brings up the old latin primal question of any examination of legal mattes: CUI BONO?
"Who benefits" from this short attack?
Also one might ask as an investor how long can it be sustained?
MarketMakers need supply to throw at the market. Pretty soon we should see a supply run at least into the 23 - 24 $ range just out of mathematical necessities which should be as meaningless as the selloff.
All that matters is patients receiving prescriptions in unheard of numerical progression!
As to your topic #2 my search brought up this certainly anecdotal first person report of VASCEPA alleviating Erectile Dysfunction..... :
"dabe
Comments82 | + Follow
I started taking Vascepa around three weeks ago. I am 72, in good physical condition, have controlled hypertension and borderline high cholesterol. As is common with males my age, I have to use cialis to engage in sexual relations. My doctor only wrote the script for Vascepa after I gave him an education. He was vaguely familiar with the medication but was unaware of the specific CV benefits which surprised me given that he was doctor in a large volume multi-disciplinary practice owned and managed by a respected, renown teaching hospital. My desire to take Vascepa was primarily to conduct my own experiment on the anti-inflammatory potential of the drug and secondarily to treat my minor cardiovascular issues given my age. Another words I wanted to see if Vascepa would ameliorate ED. Well after three weeks of taking the drug I am noticing that I am waking up with a morning wood on a frequent basis which did not occur before I started taking the medication. Coincidence or something else? I obviously can’t answer that but so far I am very pleased with the results for my primary indication. The drug may have great potential as a treatment for diseases related to systemic inflammation as well as CV issues.
17 Dec 2019, 12:37 PM"
>https://seekingalpha.com/news/3526445-stifel-softens-view-on-amarin-after-fda-nod-on-vascepa-cv-claim<
Now that would certainly bring in a few more headlines than something as common and trivial as MACE which nobody wants to think about anyway...
I wonder if the company's C-Suite is even slightly aware of this possible avenue?
Once again :
please keep up your enlightening contributions!
Another fishy STAT-News re-write of history.... it will be washed away in the flotsam of time of course but for now is feeding sceptical views:
https://www.statnews.com/2019/12/13/fda-approves-amarin-fish-oil-derived-drug-to-prevent-heart-attacks-strokes/
p.s.:
From a long term silent watcher of this board to all the other silent investors hearty congratulations for keeping up the faith without foaming at the mouth continously!
And - of course - a hearty thanks to Jesse and all the other industrious experts that kept us informed and encouraged post Adcom I. !
Probably would have given up somewhere below 1 $ but kept adding instead.
May you reap your rewards!
Heartfelt seasons greetings to One & All!